This is a significant clinical catalyst that validates DISC-3405's mechanism and supports a path to pivotal trials. Traders should watch for the next data update (RESTORE-PV and sickle cell disease) and FDA feedback on selcodebart, both expected by year-end 2026. The stock is likely to re-rate higher on reduced pipeline risk.
Price Chart
Executive Summary
Disc Medicine announced positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at the SOHO conference. The drug demonstrated a significant reduction in phlebotomy events (from 4.0 to 0.6 over 26 weeks, p<0.0001), controlled hematocrit, and was well-tolerated. This is a strong clinical proof-of-concept for a novel mechanism in a large, underserved market (~150,000 US patients), de-risking the program and supporting advancement toward pivotal development.
Key Facts
- DISC-3405 reduced mean total phlebotomy events from 4.0 to 0.6 over 26 weeks (p<0.0001) in Cohort A.
- 61.5% of patients completing 26 weeks were entirely phlebotomy-free post-baseline.
- 77.8% of patients completing the first maintenance period (weeks 12-32) remained phlebotomy-free.
- Mean hematocrit was maintained stably below 45% through week 26.
- DISC-3405 was generally well-tolerated with mild, self-limited injection site reactions.
- The company plans to provide an update on RESTORE-PV and initial Phase 1b data in sickle cell disease by end of 2026.
- Disc also expects to share FDA end-of-Phase 2 feedback and plans for pivotal development of selcodebart in MF by year-end.
Financial Impact
Positive clinical data de-risks a pipeline asset targeting a ~150,000-patient US market. No financial figures were disclosed in the filing.
Risk Factors
- Data is from a small, open-label Phase 2 trial (n=13 completers in Cohort A) and may not replicate in larger, blinded studies.
- Competition from existing PV therapies (phlebotomy, cytoreductives) and other novel agents in development.
- Regulatory and commercial execution risk remains as the drug is still investigational.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-387351 |
| Document: iron-ex99_1.htm | 0001193125-26-387351 |
| Document: 0001193125-26-387351-index-headers.html | 0001193125-26-387351 |
| Document: 0001193125-26-387351-index.html | 0001193125-26-387351 |
| Document: 0001193125-26-387351.txt | 0001193125-26-387351 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 9, 2026 22d ago | Press Release | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 3, 2026 28d ago | Insider Cluster | $79.23 $68.92 | ▲ +13.01% | ▲ +11.80% | $64.48 (+18.62%) |
Sep 2, 2026 29d ago | 144 | $79.37 $70.06 | ▼ −11.73% | ▼ −10.58% | $64.48 (−18.76%) |
Aug 27, 2026 5w ago | Insider Cluster | $82.55 $79.37 | ▼ −3.85% | ▼ −4.12% | $64.48 (−21.89%) |
Aug 18, 2026 6w ago | Insider Cluster | $80.32 $82.67 | ▲ +2.93% | ▲ +3.31% | $64.48 (−19.72%) |
Aug 14, 2026 6w ago | Insider Cluster | $80.05 $80.94 | ▲ +1.11% | ▲ +2.30% | $64.48 (−19.45%) |
Jul 30, 2026 9w ago | 8-K | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 30, 2026 9w ago | Press Release | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 14, 2026 11w ago | Insider Cluster | $76.02 $74.32 | ▼ −2.24% | ▼ −1.26% | $64.48 (−15.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access